Editas Medicine (8EM) Price & Analysis

1 Followers

8EM Stock Chart & Stats

CHF2.92

CHF0.00(0.00%)

At close: Jul 29 4:00 PM EDT

CHF2.92

CHF0.00(0.00%)

Day’s Range― - ―

52-Week RangeCHF2.09 - CHF3.00

Previous CloseN/A

Volume0.00

Average Volume (3M)N/A

Market Cap

CHF320.24M

Enterprise ValueCHF190.09

Total Cash (Recent Filing)CHF123.65M

Total Debt (Recent Filing)CHF71.97M

Price to Earnings (P/E)―

Beta5.58

Next Earnings

Aug 05, 2026

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.23

Shares OutstandingN/A

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)6.67

Price to Sales (P/S)4.49

P/FCF Ratio-1.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF5.82

Price Target Upside99.44% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)-0.8

Revenue Forecast (FY)CHF11.58M

Bulls Say, Bears Say

Bulls Say

Promising EDIT-401 Preclinical DataEDIT-401’s durable, ~90% LDL-C reductions in non-human primates and favorable pre-IND feedback materially validate Editas’s in‑vivo CRISPR approach. This de‑risks the program, strengthens the clinical pathway and regulatory dialogue, and supports long-term partnership and commercialization potential.

Extended Cash Runway From Equity RaiseThe ~$125M offering extends liquidity into the second half of 2028, providing durable runway to advance EDIT‑401 and other programs to key clinical milestones. That reduces near-term refinancing pressure and gives management time to achieve value-driving data or partnership milestones before another large capital raise.

Governance Continuity And OversightShareholder approval of directors, auditor ratification, and advisory pay support indicate governance stability and investor confidence. Strong board oversight and an established auditor are durable positives for navigating complex regulatory, clinical and licensing decisions over the medium term.

Bears Say

High Cash BurnSustained ~-$141M TTM operating and free cash flow shows heavy cash consumption to fund R&D and operations. Over months this necessitates continued access to capital or partnerships; persistent negative cash generation strains financial flexibility and raises dilution risk if additional financing is required.

Eroded Equity And Higher LeverageEquity erosion to roughly $4.4M and a ~3.9x debt-to-equity ratio materially shrink the balance-sheet cushion. A thinner equity base magnifies downside risk from trial setbacks, limits strategic optionality for deals or licensing, and increases vulnerability to adverse events over the next several quarters.

Revenue Decline And Deep LossesA recurring top-line decline (~11.5% TTM) combined with very large negative margins (EBIT ~-223%, net ~-304%) highlights that operations remain unprofitable and reliant on non‑product income. Without product revenues, sustained losses constrain ability to self‑fund development and keep dependence on markets or partners high.

Editas Medicine News

EDIT Earnings this Week: How Will it Perform?

Editas Medicine Inc. (EDIT) is scheduled to report 2nd quarter earnings on 08/05/2026. Regarding Q2 estimates, Wall Street...

1d ago

EDIT

Editas Medicine Shareholders Back Board, Pay and Auditor

An announcement from Editas Medicine ( ($EDIT) ) is now available. At its June 17, 2026 annual meeting,...

2M ago

EDIT

Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO

Jeff Bezos’ new AI venture Prometheus has raised $12B in fresh funding, pushing its valuation to about $41B....

2M ago

Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI

After Editas Medicine (EDIT) presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an...

2M ago

EDIT

TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’

TD Cowen notes that Editas Medicine (EDIT) presented “compelling preclinical data” at EAS detailing EDIT-401’s 90% reduction in...

2M ago

EDIT

Editas Medicine Raises Capital Through Public Equity Offering

An announcement from Editas Medicine ( ($EDIT) ) is now available. On May 26, 2026, Editas Medicine, Inc....

2M ago

EDIT

Editas Medicine 55.6M share Secondary priced at $2.25

Cantor Fitzgerald and Wells Fargo acted as joint book running managers for the offering. Published first on TheFly...

2M ago

EDIT

Editas Medicine Suspends Existing At-The-Market Offering Prospectus

Editas Medicine ( ($EDIT) ) has issued an update. On May 26, 2026, Editas Medicine, Inc. suspended and...

2M ago

EDIT

Editas Medicine announces common stock, warrant offering, no amount given

Editas Medicine (EDIT) announced that it has commenced an underwritten public offering of its common stock and accompanying...

2M ago

EDIT

Editas Showcases Promising EDIT-401 Data for Hyperlipidemia

The latest update is out from Editas Medicine ( ($EDIT) ). On May 25, 2026, Editas Medicine presented...

2M ago

EDIT

Analyst Maintains Buy on Editas Medicine, Reiterates $5 Price Target on EDIT-401 Progress and Strong Cash Runway

H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on EDIT stock, giving a Buy rating on...

2M ago

EDIT

Editas Medicine presented preclinical data for EDIT-401 at EAS Congress

Editas Medicine (EDIT) presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral...

2M ago

EDIT

Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data

Editas Medicine ( ($EDIT) ) has issued an update. On May 14, 2026, at the American Society of...

3M ago

EDIT

Editas Medicine’s EDIT-401 shows efficacy and safety in hyperlipidemia

Editas Medicine (EDIT) shared new preclinical data supporting the continued advancement of Editas’ lead in vivo development candidate,...

3M ago

EDIT

8EM FAQ

What was Editas Medicine Inc’s price range in the past 12 months?

Editas Medicine Inc lowest stock price was CHF2.09 and its highest was CHF3.00 in the past 12 months.

What is Editas Medicine Inc’s market cap?

Editas Medicine Inc’s market cap is CHF320.24M.

When is Editas Medicine Inc’s upcoming earnings report date?

Editas Medicine Inc’s upcoming earnings report date is Aug 05, 2026 which is tomorrow.

How were Editas Medicine Inc’s earnings last quarter?

Editas Medicine Inc released its earnings results on May 05, 2026. The company reported -CHF0.211 earnings per share for the quarter, beating the consensus estimate of -CHF0.213 by CHF0.002.

Is Editas Medicine Inc overvalued?

According to Wall Street analysts Editas Medicine Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Editas Medicine Inc pay dividends?

Editas Medicine Inc does not currently pay dividends.

What is Editas Medicine Inc’s EPS estimate?

Editas Medicine Inc’s EPS estimate is -0.22.

How many shares outstanding does Editas Medicine Inc have?

Currently, no data Available

What happened to Editas Medicine Inc’s price movement after its last earnings report?

Editas Medicine Inc reported an EPS of -CHF0.211 in its last earnings report, beating expectations of -CHF0.213. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Editas Medicine Inc?

Currently, no hedge funds are holding shares in CH:8EM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Editas Medicine Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-43.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine (8EM) Earnings & Revenues

Historic Earnings Reports

8EM Stock 12 Month Forecast

Average Price Target

CHF5.82

▲(99.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"CHF1","4":"CHF4","7":"CHF7","10":"CHF10","13":"CHF13"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12.132300299999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF12.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.823504144,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF5.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.23528008,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF3.24</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4,7,10,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.156,2.9234077153846156,3.6908154307692307,4.458223146153847,5.225630861538461,5.993038576923077,6.760446292307693,7.527854007692307,8.295261723076923,9.062669438461537,9.830077153846153,10.597484869230769,11.364892584615385,{"y":12.132300299999999,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.156,2.4381157033846157,2.720231406769231,3.0023471101538464,3.284462813538462,3.566578516923077,3.8486942203076926,4.130809923692308,4.412925627076923,4.695041330461539,4.977157033846154,5.25927273723077,5.5413884406153855,{"y":5.823504144,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.156,2.239021544615385,2.3220430892307693,2.405064633846154,2.4880861784615385,2.5711077230769233,2.6541292676923076,2.7371508123076924,2.8201723569230768,2.9031939015384616,2.986215446153846,3.0692369907692307,3.1522585353846155,{"y":3.23528008,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.919,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.156,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >